This video was recorded at View Point Calgary, which took place on May 6, 2023.
In December 2022, the first gene therapy for an eye disease was approved for public funding in Alberta. This treatment, called Luxturna, slows and may even restore some vision loss caused by mutations in the RPE65 gene. Dr. Mark Seamone is one of the doctors at the forefront of administrating this treatment in Canada. Dr. Seamone joined us to discuss how gene therapy works, provide an update on Luxturna, and share some insights on the future of gene therapy.
View Point is proudly presented by Bayer and supported by Abbvie, Apellis, Beacon Therapeutics, Janssen, MeiraGTx, Novartis and Roche.
To learn more visit [ Ссылка ]
STAY CONNECTED
Facebook: [ Ссылка ]
Instagram: [ Ссылка ]
LinkedIn: [ Ссылка ]
Sign-up for our monthly e-newsletter: [ Ссылка ]
CONTACT US
General Inquiries: info@fightingblindness.ca
Health Information Line: 1.888.626.2995 | healthinfo@fightingblindness.ca
ABOUT FIGHTING BLINDNESS CANADA
Fighting Blindness Canada (FBC) is Canada’s leading private funder of vision research. We offer hope to Canadians by identifying the best, most promising research that is driving treatments and cures for blinding eye diseases, and by raising and stewarding funds to support this essential, sight-saving research. All of the research and educational initiatives we fund, support our goals of understanding why vision loss occurs, how it can be slowed or stopped, and how sight can be restored. Learn more about Fighting Blindness Canada: [ Ссылка ]
DONATE: Support the advancement of sight-saving research, make a donation today: [ Ссылка ]
